Recombinant Human GRK6/GPRK6 Protein (GST & His Tag) (Active)

Cat. No : CDRP-00099

size:

Target Information
Target Name	GRK6/GPRK6
Synonyms	GPRK6
UniProt ID	O95971
Accession	P43250-2

Product Details
Expression Host	Baculovirus-Insect Cells
Species	Human
Tag	N-His & GST
Molar Mass	95.1 kDa
Sequence	Tyr 35-Leu 357

Background
G protein-coupled receptor kinase 6, also known as G protein-coupled receptor kinase GRK6, GRK6 and GPRK6, is a lipid-anchor protein which belongs to theprotein kinase superfamily, AGC Ser/Thr protein kinase family and GPRK subfamily. GRK6/GPRK6 contains oneAGC-kinase C-terminal domain, oneprotein kinase domain and oneRGS domain. This protein phosphorylates the activated forms of G protein-coupled receptors thus initiating their deactivation. Several transcript variants encoding different isoforms have been described. GRK6/ GPRK6 is widely expressed. GRK6/GPRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. GRK6 also appears to be involved in responses to morphine. Inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

Background

G protein-coupled receptor kinase 6, also known as G protein-coupled receptor kinase GRK6, GRK6 and GPRK6, is a lipid-anchor protein which belongs to theprotein kinase superfamily, AGC Ser/Thr protein kinase family and GPRK subfamily. GRK6/GPRK6 contains oneAGC-kinase C-terminal domain, oneprotein kinase domain and oneRGS domain. This protein phosphorylates the activated forms of G protein-coupled receptors thus initiating their deactivation. Several transcript variants encoding different isoforms have been described. GRK6/ GPRK6 is widely expressed. GRK6/GPRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. GRK6 also appears to be involved in responses to morphine. Inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

Properties
Purity	>98% as determined by reducing SDS-PAGE.
Formulation	Supplied as sterile solution of 20 mM Tris, 500 mM NaCl, 2 mM GSH, 0.5 mM PMSF, pH7.4.
Reconstitution	Please refer to the printed manual for detailed information.
Shipping	This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs.
Storage	Store at < -20 °C, stable for 6 months. Please minimize freeze-thaw cycles.

! For research use only. Not intended for any clinical use.